|Cat. No. :
|Product Overview :
||Recombinant human KDR, a 764 amino acids protein with 6 His tag at C-terminus, and has a calculated MW of 86.2 kDa. DTT-reduced protein migrates as 100-110 kDa protein due to glycosylation.
||Kinase insert domain receptor (KDR) is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1).VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding.
||Recombinant human KDR (rh KDR) Met1-Glu764 (Accession AAI31823) was expressed in human 293 cells (HEK293).
||Bulk protein in a 0.22 μm filtered solution of PBS, pH 7.4 and delivered as lyophilized powder, Normally 2-7% Mannitol and Trehalose before lyophilization are added as protectants. It is recommended to reconstitute the lyophilized rh KDR in sterile dH2O.
||>90% as determined by SDS-PAGE of 2 μg reduced rh KDR. All lots are greater than 90% pure.
||Less than 1.0 EU per 1 μg of the rh KDR by the LAL method.
||Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.